don’t know much about eyebio - maybe it’s promising enough to wipe VEGF inhibitors market share by a large amount.
Reminds of me of pharmaxis - they had a big drug prospect which actually got FDA approval yet by the time it got to revenue generation phase it fell flat as better treatments where available.
Maybe this is holding back OPT?
don’t know much about eyebio - maybe it’s promising enough to...
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
70.0¢ |
Change
-0.060(7.89%) |
Mkt cap ! $861.7M | |||
| Open | High | Low | Value | Volume |
| 74.5¢ | 75.3¢ | 70.0¢ | $2.454M | 3.418M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 24553 | 69.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 72.0¢ | 10165 | 1 |
View Market Depth
| Last trade - 16.10pm 14/11/2024 (20 minute delay) ? |
| OPT (ASX) Chart |